Biljana N Horn

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies
    Biljana Horn
    Allergy Immunology and Blood and Marrow Transplant Division at Benioff Children s Hospital at University of California San Francisco, San Francisco, California Electronic address
    Biol Blood Marrow Transplant 21:729-37. 2015
  2. doi Unresolved issues in hematopoietic stem cell transplantation for severe combined immunodeficiency: need for safer conditioning and reduced late effects
    Biljana Horn
    Division of Allergy, Immunology, and Blood and Marrow Transplantation, Benioff Children s Hospital, University of California, San Francisco, San Francisco, CA, USA
    J Allergy Clin Immunol 131:1306-11. 2013
  3. doi Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis
    Jonathan Strober
    UCSF Children s Hospital, 505 Parnassus Ave, M 659, San Francisco, CA 94143 1278, USA
    Arch Neurol 66:659-61. 2009
  4. doi Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies
    B Horn
    Department of Pediatrics, UCSF Medical Center, University of California, San Francisco, CA 94143 1278, USA
    Bone Marrow Transplant 43:469-76. 2009
  5. ncbi Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML
    B Horn
    Department of Pediatrics, University of California San Francisco, San Francisco, CA 94143 1278, USA
    Bone Marrow Transplant 37:263-9. 2006
  6. pmc Massage for children undergoing hematopoietic cell transplantation: a qualitative report
    Sara L Ackerman
    Department of General Internal Medicine, The University of Califorina, San Francisco, CA 94143, USA
    Evid Based Complement Alternat Med 2012:792042. 2012
  7. doi A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency
    Christopher C Dvorak
    Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplant, University of California San Francisco, Benioff Children s Hospital, San Francisco, CA, USA
    Pediatr Transplant 18:609-16. 2014
  8. doi Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions
    C C Dvorak
    UCSF Children s Hospital, University of California, San Francisco, USA
    Bone Marrow Transplant 44:805-12. 2009
  9. pmc Hematopoietic cell transplant and use of massage for improved symptom management: results from a pilot randomized control trial
    Wolf E Mehling
    Osher Center for Integrative Medicine, University of California, San Francisco, CA 94115, USA
    Evid Based Complement Alternat Med 2012:450150. 2012
  10. pmc A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency
    Christopher C Dvorak
    Division of Pediatric Allergy, Immunology and Blood and Marrow Transplant, University of California San Francisco Benioff Children s Hospital, San Francisco, CA, USA
    Pediatr Transplant 18:602-8. 2014

Collaborators

Detail Information

Publications15

  1. doi Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies
    Biljana Horn
    Allergy Immunology and Blood and Marrow Transplant Division at Benioff Children s Hospital at University of California San Francisco, San Francisco, California Electronic address
    Biol Blood Marrow Transplant 21:729-37. 2015
    ..Evidence of disease before transplantation remained a significant predictor of relapse, whereas development of chronic GVHD was protective against relapse. ..
  2. doi Unresolved issues in hematopoietic stem cell transplantation for severe combined immunodeficiency: need for safer conditioning and reduced late effects
    Biljana Horn
    Division of Allergy, Immunology, and Blood and Marrow Transplantation, Benioff Children s Hospital, University of California, San Francisco, San Francisco, CA, USA
    J Allergy Clin Immunol 131:1306-11. 2013
    ..Finally, development of new nontoxic conditioning regimens for HCT that can be safely used in very young children is required...
  3. doi Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis
    Jonathan Strober
    UCSF Children s Hospital, 505 Parnassus Ave, M 659, San Francisco, CA 94143 1278, USA
    Arch Neurol 66:659-61. 2009
    ..To describe a patient with intractable myasthenia gravis (MG) who was treated with a matched sibling peripheral blood stem cell transplantation...
  4. doi Feasibility study of preemptive withdrawal of immunosuppression based on chimerism testing in children undergoing myeloablative allogeneic transplantation for hematologic malignancies
    B Horn
    Department of Pediatrics, UCSF Medical Center, University of California, San Francisco, CA 94143 1278, USA
    Bone Marrow Transplant 43:469-76. 2009
    ..Further studies correlating lineage-specific chimerism and minimal residual disease are required. The goal of preemptive immunotherapy should be to achieve full donor chimerism in WB in CD3+ and leukemia-specific lineages...
  5. ncbi Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML
    B Horn
    Department of Pediatrics, University of California San Francisco, San Francisco, CA 94143 1278, USA
    Bone Marrow Transplant 37:263-9. 2006
    ..However, it did not provide sustained engraftment in the majority of children with nonmalignancies undergoing mismatched unrelated donor transplants...
  6. pmc Massage for children undergoing hematopoietic cell transplantation: a qualitative report
    Sara L Ackerman
    Department of General Internal Medicine, The University of Califorina, San Francisco, CA 94143, USA
    Evid Based Complement Alternat Med 2012:792042. 2012
    ....
  7. doi A trial of alemtuzumab adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency
    Christopher C Dvorak
    Division of Pediatric Allergy, Immunology, and Blood and Marrow Transplant, University of California San Francisco, Benioff Children s Hospital, San Francisco, CA, USA
    Pediatr Transplant 18:609-16. 2014
    ..Although well-tolerated, alemtuzumab failed to overcome immunologic barriers to donor engraftment. Furthermore, alemtuzumab may slow T-cell development in patients with SCID in the setting of a T-cell depleted graft. ..
  8. doi Clinical and immunologic outcomes following haplocompatible donor lymphocyte infusions
    C C Dvorak
    UCSF Children s Hospital, University of California, San Francisco, USA
    Bone Marrow Transplant 44:805-12. 2009
    ..The 1-year overall survival following haplocompatible DLI was 71% (95% CI, 59-83%), with a median follow-up of 16 months from the first DLI...
  9. pmc Hematopoietic cell transplant and use of massage for improved symptom management: results from a pilot randomized control trial
    Wolf E Mehling
    Osher Center for Integrative Medicine, University of California, San Francisco, CA 94115, USA
    Evid Based Complement Alternat Med 2012:450150. 2012
    ..Discussion. Feasibility of studying massage-acupressure was established in children undergoing HCT. Larger studies are needed to test the efficacy of such interventions in reducing HCT-associated symptoms in children...
  10. pmc A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency
    Christopher C Dvorak
    Division of Pediatric Allergy, Immunology and Blood and Marrow Transplant, University of California San Francisco Benioff Children s Hospital, San Francisco, CA, USA
    Pediatr Transplant 18:602-8. 2014
    ..Although well tolerated, G-CSF plus plerixafor alone failed to overcome physical barriers to donor engraftment. ..
  11. doi Clinical update on graft-versus-host disease in children
    Deborah S Goddard
    Department of Dermatology, Division of Pediatric Dermatology, University of California, San Francisco, CA 94115, USA
    Semin Cutan Med Surg 29:92-105. 2010
    ..We discuss 5 cases with clinico-pathologic correlation to illustrate the key concepts and principles underlying the diagnosis and management of both acute and chronic GVHD...
  12. ncbi Bone marrow transplantation for T-B- severe combined immunodeficiency disease in Athabascan-speaking native Americans
    K DeSantes
    Department of Pediatrics Bone Marrow Transplant Division, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143-1278, USA
    Bone Marrow Transplant 27:703-9. 2001
    ..With T cell depletion of haplocompatible marrow, conditioning with immunosuppressive therapy may be necessary; however, children with SCIDA who were treated with intensive immunosuppressive and myeloablative therapy had a poor outcome...
  13. ncbi Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma
    B Horn
    Department of Pediatrics, University of California, San Francisco, CA, USA
    Bone Marrow Transplant 29:409-15. 2002
    ..8, P = 0.03). Larger studies of patients with neuroblastoma are necessary in order to confirm our findings and better define the risk factors for VOD development in neuroblastoma patients...
  14. ncbi Immune reconstitution, infectious complications and post transplant supportive care measures after autologous blood and marrow transplantation in children
    J Machatschek
    University of Kiel Medical Center, Germany
    Bone Marrow Transplant 32:687-93. 2003
    ..Post-transplant supportive care measures may be discontinued at 6 months post ABMT in most children, as the risk of infection decreases after that time...
  15. ncbi Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003
    M A Pulsipher
    Primary Children s Medical Center, Salt Lake City, UT, USA
    Bone Marrow Transplant 35:361-7. 2005
    ..Younger children utilize more medical resources and children <20 kg usually require a single blood product exposure...